AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.257

+0.0072.80%

Volume:414.17K

Turnover:106.25K

Market Cap:82.63M

PE:-0.81

High:0.262

Open:0.250

Low:0.250

Close:0.250

52wk High:1.496

52wk Low:0.240

Shares:321.52M

Float Shares:254.20M

Volume Ratio:0.82

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.316

EPS(LYR):-0.316

ROE:-84.54%

ROA:-37.27%

PB:1.83

PE(LYR):-0.81

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+1.37%

Capital Flow

Inflow:

Outflow:

News

Dimerix Appoints CFO

MT Newswires Live

FiberPro Secures KRW4.89 Billion Inertial Measurement Unit Supply Contract; Shares Jump 18%

MT Newswires Live

Imugene Ltd-Executive Update

THOMSON REUTERS

Imugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.257,"timestamp":1770685491017,"preClose":0.25,"halted":0,"volume":414170,"delay":0,"changeRate":0.028000000000000025,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":321515615,"eps":-0.315594,"marketStatus":"Trading","change":0.007,"latestTime":"02-10 12:05:47 AEDT","open":0.25,"high":0.262,"low":0.25,"amount":106250,"amplitude":0.048,"askPrice":0.26,"askSize":7100,"bidPrice":0.255,"bidSize":152350,"shortable":3,"etf":0,"ttmEps":-0.315594,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.25,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.817313,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-37.27%","roe":"-84.54%","lyrEps":-0.315594,"volumeRatio":0.817313,"shares":321515615,"dividePrice":0,"high":0.262,"amplitude":0.048,"preClose":0.25,"low":0.25,"week52Low":0.24,"pbRate":"1.83","psRate":"18.79","week52High":1.496,"institutionHeld":0,"latestPrice":0.257,"committee":0.910944,"eps":-0.315594,"divideRate":0,"volume":414170,"delay":0,"ttmEps":-0.315594,"open":0.25,"prevYearClose":0.365,"prevWeekClose":0.245,"prevMonthClose":0.28,"prevQuarterClose":0.365,"fiveDayClose":0.275,"twentyDayClose":0.34,"sixtyDayClose":0.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605114264","title":"Dimerix Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605114264","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605114264?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:24","pubTimestamp":1768947849,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) appointed Mike Tonroe as chief financial officer, effective Jan. 29, according to a Wednesday filing with the Australian bourse.Tonroe brings over 30 years of experience, having most recently served as the CFO of Imugene (ASX:IMU), the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK7067","IMU.AU","DXB.AU"],"gpt_icon":0},{"id":"2604165686","title":"FiberPro Secures KRW4.89 Billion Inertial Measurement Unit Supply Contract; Shares Jump 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604165686","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604165686?lang=en_us&edition=fundamental","pubTime":"2026-01-20 12:02","pubTimestamp":1768881728,"startTime":"0","endTime":"0","summary":"FiberPro (KOSDAQ:368770) secured an inertial measurement unit (IMU) supply contract from Viavi Solutions, according to a Tuesday filing with the Korean Exchange.The deal is valued at 4.89 billion won.Shares of the precise motion measurement solutions provider jumped nearly 18% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2600055351","title":"Imugene Ltd-Executive Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2600055351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600055351?lang=en_us&edition=fundamental","pubTime":"2026-01-02 12:46","pubTimestamp":1767329217,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nTUECCVBQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2589438379","title":"Imugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589438379","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589438379?lang=en_us&edition=fundamental","pubTime":"2025-12-08 11:38","pubTimestamp":1765165122,"startTime":"0","endTime":"0","summary":"Imugene  said the US Food and Drug Administration  confirmed data from the current phase 1b study with azer-cel therapy candidate plus IL-2 dosing regimen, including lymphodepletion conditioning, along with the safety profile, supported advancing to phase three registrational study, according to a Monday Australian bourse filing.It received written minutes from the FDA following its recent Type C meeting. This included directional confirmation that its proposed regimen for the pivotal program, which includes augmented lymphodepletion followed by a flat 500 million cell dose of azer-cel with 14 days of subcutaneous low-dose IL-2, is appropriate.The regulator endorsed the firm's dual-end point strategy, with overall response rate and durability being used for accelerated approval, and progression-free survival being used for full approval. It also asked that the control arm include several investigator-choice therapies.The third line and later diffuse large B-cell lymphoma, including pat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.013651}]}}